The positive reception of Phase III data for GW Pharmaceuticals PLC's cannabinoid therapy Epidiolex for Dravet syndrome, a severe type of pediatric epilepsy, in the New England Journal of Medicine is an important step for pharmaceutical-grade cannabinoids as a therapeutic option for neurological disorders as well as other diseases.
Derived from the marijuana plant, Epidiolex includes cannabidiol (CBD) but not the psychoactive tetrahydrocannabinol (THC). The drug is one of...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
